Guggenheim initiated coverage of Benitec Biopharma with a Buy rating and $17 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTC:
- Benitec Biopharma Shareholders Approve Key Proposals
- Benitec Biopharma initiated with an Outperform at Leerink
- Benitec Biopharma Reports Promising Interim Study Results
- Benitec Biopharma’s BB-301 shows efficacy in Phase 1b/2a study of OPMD
- Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study